June 13, 2023 7:48am

Bets should be placed on the downtrodden, don’t ignore the up sliders – they will be plucked, just a matter of sessions

Pre-open Indications: 3 Positive, 1 Negative and 1 Sell into Strength Indications

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Never leave an investor uninformed! 

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday

 

Dow futures are UP +0.03% or (+10 points), S&P futures are UP +0.10% or (+4 point) and NASDAQ futures are UP +0.26% or (+39 points) early in the pre-open – so far

Stock futures ticked higher Tuesday ahead of the U.S. inflation report,

Europe markets opened higher and went mixed,

Asia-Pacific markets rose.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes jumped on Monday to the highest in 13 months as traders hoped the Fed will skip/side-step hiking rates when the central bank decides on policy Wednesday.

Last night, the Dow closed UP +189.55 points (+0.56%), the S&P closed UP +40.08 points (+0.93%) while the Nasdaq closed UP +202.78 points (+1.53%)

 

Economic Data Docket: May CPI

 

Monday (6/12) … RegMed Investors’ (RMi) closing bell: “validation of sector by Novartis’ NV (NVS) acquisition of Chinook Therapeutics (KDNY) and Intellia Therapeutics’ (NTLA) potential cure. A maybe – the Fed could skip a rate hike this week.” …  https://www.regmedinvestors.com/articles/12999

 

Ebb and flow:

Q2/23 – 2 negative and 6 positive closes

·         May – 10 negative and 12 positive closes

·         April ended - 1 holiday, 8 positive close and 11 negative closes

Q1/23 –

·         March – ended with 10 positive and 13 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indication:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

AxoGen (AXGN) closed down -$0.16 with a positive +$0.27 or +2.95% aftermarket indication

Vericel (VCEL) closed down -$0.82 with a positive +$0.82 or +2.40% aftermarket indication

Intellia Therapeutics (NTLA) closed up +$0.37 with a positive +$0.47 or +1.08% pre-open indication

 

Negative Indication:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

BioLife Solutions (BLFS) closed up +$1.32 with a negative -$0.56 or -2.33% aftermarket indication

 

Sell into Strength:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Chinook Therapeutics (KDNY) closed up +$13.99 with a negative -$0.18 or -0.47% pre-open indication

 

The BOTTOM LINE:

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all, as I try to keep it simple and short!

The title says it all …

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!

At ANY time, this week, be ready to take partial profits and exit losers.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

 

NO AI here